衰弱与肌少症对死亡和失能的差异性关联:支持衰弱临床亚型的见解
本研究基于西班牙Toledo健康老龄化研究1531名65岁以上参与者,评估肌少症是否改变衰弱对死亡和失能的预后。结果显示衰弱与死亡关联在调整肌少症后仍显著,而肌少症与死亡关联在同时纳入衰弱后不再显著;失能方面衰弱与肌少症存在显著交互,两者同时存在才预测失能恶化。
要点
- 衰弱和衰弱前期与死亡关联在调整肌少症后仍显著。
- 肌少症与死亡关联在同时纳入衰弱后减弱且不再显著。
- 衰弱与肌少症对失能恶化存在显著交互,两者同时存在才预测失能恶化。
核心结论
- 肌少症在衰弱相关的功能损害风险增加中起重要作用,但在死亡风险中似乎并非如此。
- 该发现提示诊断衰弱后应将肌少症评估作为临床工作的基石。
研究设计与样本
- 西班牙基于人群的纵向研究,纳入Toledo健康老龄化研究1531名65岁以上参与者。
- 肌少症按Foundation for the National Institutes of Health标准评估,衰弱按Fried衰弱表型评估。
- 死亡通过National Death Index评估,功能状态采用Katz指数确定。
- 采用多因素logistic和比例风险模型,调整年龄、性别、基线功能和共病。
主要发现
- 平均年龄75.4岁(SD 5.9),衰弱70人(4.6%),衰弱前期565人(36.9%),肌少症435人(28.4%)。
- 死亡平均随访5.5年,功能恶化平均随访3.0年;184人死亡(12%),324人功能恶化(24.8%)。
- 衰弱与死亡关联在调整肌少症后仍显著(HR 3.09,95%CI 1.84-5.18,P<.001);衰弱前期亦显著(HR 1.58,95%CI 1.12-2.24,P=.01)。
- 肌少症与死亡关联在同时纳入衰弱和肌少症后减弱且不显著(HR 1.43,95%CI 0.99-2.07,P=.057)。
- 失能模型中衰弱与肌少症交互显著(P=.016),两者同时存在才预测失能恶化。
临床怎么用
- 诊断衰弱后应评估肌少症,以识别功能恶化高风险亚型。
- 衰弱合并肌少症者可能需重点关注失能预防,而非仅关注死亡风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Sarcopenia and frailty have been shown separately to predict disability and death in old age. Our aim was to determine if sarcopenia may modify the prognosis of frailty regarding both mortality and disability, raising the existence of clinical subtypes of frailty depending on the presence of sarcopenia. DESIGN: A Spanish longitudinal population-based study. SETTING AND PARTICIPANTS: The population consists of 1531 participants (>65 years of age) from the Toledo Study of Health Aging. METHODS: Sarcopenia and frailty were assessed following Foundation for the National Institutes of Health criteria and the Fried Frailty Phenotype, respectively. Mortality was assessed using the National Death Index. Functional status was determined using Katz index. We ran multivariate logistics and proportional hazards models adjusting for age, sex, baseline function, and comorbidities. RESULTS: Mean age was 75.4 years (SD 5.9). Overall, 70 participants were frail (4.6%), 565 prefrail (36.9%), and 435 sarcopenic (28.4%). Mean follow-up was 5.5 and 3.0 years for death and worsening function, respectively. Furthermore, 184 participants died (12%) and 324 worsened their functioning (24.8%). Frailty and prefrailty were associated with mortality and remained significant after adjustment by sarcopenia [hazard risk (HR) 3.09, 95% confidence interval (CI) 1.84-5.18; P < .001; HR 1.58, 95% CI 1.12-2.24, P = .01]. However, the association of sarcopenia with mortality was reduced and became nonsignificant (HR 1.43, 95% CI 0.99-2.07, P = .057) when both frailty and sarcopenia were included in the same model. In the disability model, frailty and sarcopenia showed a statistically significant interaction (P = .016): both had to be present to predict worsening of disability. CONCLUSIONS AND IMPLICATIONS: Sarcopenia plays a relevant role in the increased risk of functional impairment associated to frailty, but that seems not to be the case with mortality. This finding raises the need of assessing sarcopenia as a cornerstone of the clinical work after diagnosing frailty.
引用
- Davies B, Walter S, Rodríguez-Laso A, et al. Differential Association of Frailty and Sarcopenia With Mortality and Disability: Insight Supporting Clinical Subtypes of Frailty. J Am Med Dir Assoc. 2022. PMID: 35472314. doi:10.1016/j.jamda.2022.03.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。